AperçuGraphiqueActualitésTraderScreen

L&S Knock-Out ZEG/  DE000LX20S87  /

EUWAX
15/11/2024  08:11:21 Chg.0.000 Bid22:00:23 Demandez à22:00:23 Sous-jacent Prix d'exercice Date d'expiration Type d'option
0.090EUR 0.00% -
Bid taille: -		 -
Ask la taille: -		 ASTRAZENECA PLC D... 114.5849 - 31/12/2078 Call
TeleTrader 12/11 AstraZeneca's revenue in Q3 rises 21% to $13.5B
GlobeNewswire 12/08 Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire 08/08 Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire 06/08 Cellectis Provides Financial Results for the Second Quarter 2024
TeleTrader 25/07 AstraZeneca's Q2 revenue up by 13% to $12.94B
GlobeNewswire 15/07 AstraZeneca Closes Acquisition of Amolyt Pharma
GlobeNewswire 26/06 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 18/06 Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire 18/06 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 13/06 Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire 28/05 Cellectis Reports Financial Results for First Quarter 2024
TeleTrader 21/05 AstraZeneca to deliver $80B total revenue by 2030
TeleTrader 20/05 AstraZeneca to build $1.5B plant in Singapore
GlobeNewswire 08/05 Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire 06/05 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 06/05 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 29/04 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
TeleTrader 25/04 Europe opens mostly down after corporate earnings
TeleTrader 25/04 AstraZeneca Q1 revenue jumps 19% to $12.7B
GlobeNewswire 28/03 HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
TeleTrader 19/03 AstraZeneca to acquire Fusion for $2 billion
GlobeNewswire 18/03 AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement
TeleTrader 14/03 AstraZeneca to acquire Amolyt Pharma for $1.05B
GlobeNewswire 14/03 Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
GlobeNewswire 28/02 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates